Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells

BMC Gastroenterology

Volumn 15, Issue 1, 2015, Pages

  Chong, Lee Won ^a,b   Hsu, Yi Chao ^c   Lee, Ting Fang ^a   Lin, Yun ^d   Chiu, Yung Tsung ^e   Yang, Kuo Ching ^b   Wu, Jaw Ching ^a,f   Huang, Yi Tsau ^a,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c MACKAY MEDICAL COLLEGE   (Taiwan)

^d NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Fibrogenesis; Hepatocyte; Non alcoholic fatty liver disease; Paracrine effect; Statins; Steatohepatitis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; FLUINDOSTATIN; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; PALMITIC ACID; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; ACTA2 PROTEIN, HUMAN; ACTIN; CHOLINE; CONDITIONED MEDIUM; CYBB PROTEIN, HUMAN; CYBB PROTEIN, RAT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MEMBRANE PROTEIN; MONOUNSATURATED FATTY ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMOOTH MUSCLE ACTIN, RAT; TUMOR NECROSIS FACTOR;

ADULT; ALPHA SMA GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; COL1 GENE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HEPG2 CELL LINE; HISTOPATHOLOGY; HSC T6 CELL LINE; HUMAN; HUMAN CELL; ICAM 1 GENE; IL 6 GENE; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL; TGF BETA1 GENE; TIMP 1 GENE; TNF ALPHA GENE; WESTERN BLOTTING; ANIMAL; COMPLICATION; CONDITIONED MEDIUM; DIET; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHARMACOLOGY; PHYSIOLOGY; WISTAR RAT;

ACTINS; ANIMALS; CHOLINE; COLLAGEN TYPE I; CULTURE MEDIA, CONDITIONED; DIET; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION; HEP G2 CELLS; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PALMITIC ACID; PARACRINE COMMUNICATION; RATS; RATS, WISTAR; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924910736     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/s12876-015-0248-8     Document Type: Article

References (38)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-31.
2. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87(7):679-95.
3. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res. 2013;52(1):165-74.
4. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012;12:20.
5. Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47(11):869-80.
6. Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal. 2014;20(17):2854-72.
7. Cao S, Zhang X, Edwards JP, Mosser DM. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem. 2006;281(36):26041-50.
8. Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond). 2014;11:23.
9. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. 2012;159(6):477-86.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
11. Roglans N, Sanguino E, Peris C, Alegret M, Vazquez M, Adzet T, et al. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats. J Pharmacol Exp Ther. 2002;302(1):232-9.
12. Egawa T, Toda K, Nemoto Y, Ono M, Akisaw N, Saibara T, et al. Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar-/-) mice. Lipids. 2003;38(5):519-23.
13. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23(11):1643-7.
14. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008;57(12):1711-8.
15. Lin YL, Wu CH, Luo MH, Huang YJ, Wang CN, Shiao MS, et al. In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. J Ethnopharmacol. 2006;105(1-2):215-22.
16. Parkes JG, Templeton DM. Effects of retinol and hepatocyte-conditioned medium on cultured rat hepatic stellate cells. Ann Clin Lab Sci. 2003;33(3):295-305.
17. Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res. 2000;41(6):882-93.
18. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci. 2006;13(3):403-18.
19. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Antifibrotic effects of triptolide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. Phytother Res. 2011;25(7):990-9.
20. Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Buttner R, et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19(8):996-1005.
21. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol. 2003;18(11):1272-82.
22. Takeuchi-Yorimoto A, Noto T, Yamada A, Miyamae Y, Oishi Y, Matsumoto M. Persistent fibrosis in the liver of choline-deficient and iron-supplemented l-amino acid-defined diet-induced nonalcoholic steatohepatitis rat due to continuing oxidative stress after choline supplementation. Toxicol Appl Pharmacol. 2013;268(3):264-77.
23. Tsai MK, Lin YL, Huang YT. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol. 2010;242(2):155-64.
24. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem. 1985;33(8):737-43.
25. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(4):195-203.
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
27. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive, or fibrogenic? Gastroenterology. 2006;131(1):272-5.
28. De Minicis S, Seki E, Paik YH, Osterreicher CH, Kodama Y, Kluwe J, et al. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology. 2010;52(4):1420-30.
29. Aram G, Potter JJ, Liu X, Wang L, Torbenson MS, Mezey E. Deficiency of nicotinamide adenine dinucleotide phosphate, reduced form oxidase enhances hepatocellular injury but attenuates fibrosis after chronic carbon tetrachloride administration. Hepatology. 2009;49(3):911-9.
30. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112(9):1383-94.
31. Tobar N, Villar V, Santibanez JF. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem. 2010;340(1-2):195-202.
32. Mantawy EM, Tadros MG, Awad AS, Hassan DA, El-Demerdash E. Insights antifibrotic mechanism of methyl palmitate: impact on nuclear factor kappa B and proinflammatory cytokines. Toxicol Appl Pharmacol. 2012;258(1):134-44.
33. Abe Y, Izumi T, Urabe A, Nagai M, Taniguchi I, Ikewaki K, et al. Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress. Cardiovasc Drugs Ther. 2006;20(4):273-80.
34. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol. 2007;170(4):1165-77.
35. Ikeuchi H, Kuroiwa T, Yamashita S, Hiramatsu N, Maeshima A, Kaneko Y, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis. Nephron Exp Nephrol. 2004;97(4):e115-22.
36. Mukai Y, Wang CY, Rikitake Y, Liao JK. Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol. 2007;292(4):H1937-42.
37. Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, Shen C. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One. 2013;8(10):e76538.
38. Miyaki T, Nojiri S, Shinkai N, Kusakabe A, Matsuura K, Iio E, et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol Res. 2011;41(4):375-85.